Voyager Therapeutics announces new data from two preclinical programs

Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on tau silencing gene therapy VY1706 and anti-tau antibody VY7523 will be presented at the upcoming 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, taking place April 1-5, 2025, in Vienna. Additionally, Voyager announced it will host a live webcast recapping key AD/PD(TM) 2025 data at 4:30 p.m. ET on Monday, April 7, 2025. New preclinical data from a non-human primate study show that a single, intravenous 1.3E13 vg/kg dose of Voyager’s tau silencing gene therapy VY1706 resulted in dose-dependent knockdown of tau mRNA and tau protein. Results were sustained up to three months following dosing, and VY1706 was well-tolerated at both the 5-week and 11-week timepoints assessed in the study. New preclinical data show that the murine version of Voyager’s VY7523 demonstrates selectivity for binding pathologic tau tangles. Additionally, Voyager assessed several anti-tau antibodies using a P301S mouse hippocampal seeding model of tau spread. Antibodies that bind the N-terminal of tau and previously failed to achieve their primary endpoints in clinical studies also failed to significantly reduce tau spread in the model.